Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy
This study aimed to analyze the treatment and outcomes of older glioblastoma patients. Forty-four patients older than 70 years of age were referred to the Paul Strauss Center for chemotherapy and radiotherapy. The median age was 75.5 years old (range: 70–84), and the patients included 18 females and...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2013-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/5/3/1177 |
| _version_ | 1797721160889139200 |
|---|---|
| author | Georges Noël Pierre Kehrli Roland Schott Céline Vigneron Nicolas Bauer Jean-Baptiste Clavier Sokha Eav Hélène Nehme-Schuster Delphine Antoni Ludovic T. Nguyen Socheat Touch |
| author_facet | Georges Noël Pierre Kehrli Roland Schott Céline Vigneron Nicolas Bauer Jean-Baptiste Clavier Sokha Eav Hélène Nehme-Schuster Delphine Antoni Ludovic T. Nguyen Socheat Touch |
| author_sort | Georges Noël |
| collection | DOAJ |
| description | This study aimed to analyze the treatment and outcomes of older glioblastoma patients. Forty-four patients older than 70 years of age were referred to the Paul Strauss Center for chemotherapy and radiotherapy. The median age was 75.5 years old (range: 70–84), and the patients included 18 females and 26 males. The median Karnofsky index (KI) was 70%. The Charlson indices varied from 4 to 6. All of the patients underwent surgery. O6-methylguanine–DNA methyltransferase (MGMT) methylation status was determined in 25 patients. All of the patients received radiation therapy. Thirty-eight patients adhered to a hypofractionated radiation therapy schedule and six patients to a normofractionated schedule. Neoadjuvant, concomitant and adjuvant chemotherapy regimens were administered to 12, 35 and 20 patients, respectively. At the time of this analysis, 41 patients had died. The median time to relapse was 6.7 months. Twenty-nine patients relapsed, and 10 patients received chemotherapy upon relapse. The median overall survival (OS) was 7.2 months and the one- and two-year OS rates were 32% and 12%, respectively. In a multivariate analysis, only the Karnofsky index was a prognostic factor. Hypofractionated radiotherapy and chemotherapy with temozolomide are feasible and acceptably tolerated in older patients. However, relevant prognostic factors are needed to optimize treatment proposals. |
| first_indexed | 2024-03-12T09:30:00Z |
| format | Article |
| id | doaj.art-e38b04bd326c4a7684ea1bd50dbfd851 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T09:30:00Z |
| publishDate | 2013-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-e38b04bd326c4a7684ea1bd50dbfd8512023-09-02T13:55:23ZengMDPI AGCancers2072-66942013-09-01531177119810.3390/cancers5031177Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated RadiotherapyGeorges NoëlPierre KehrliRoland SchottCéline VigneronNicolas BauerJean-Baptiste ClavierSokha EavHélène Nehme-SchusterDelphine AntoniLudovic T. NguyenSocheat TouchThis study aimed to analyze the treatment and outcomes of older glioblastoma patients. Forty-four patients older than 70 years of age were referred to the Paul Strauss Center for chemotherapy and radiotherapy. The median age was 75.5 years old (range: 70–84), and the patients included 18 females and 26 males. The median Karnofsky index (KI) was 70%. The Charlson indices varied from 4 to 6. All of the patients underwent surgery. O6-methylguanine–DNA methyltransferase (MGMT) methylation status was determined in 25 patients. All of the patients received radiation therapy. Thirty-eight patients adhered to a hypofractionated radiation therapy schedule and six patients to a normofractionated schedule. Neoadjuvant, concomitant and adjuvant chemotherapy regimens were administered to 12, 35 and 20 patients, respectively. At the time of this analysis, 41 patients had died. The median time to relapse was 6.7 months. Twenty-nine patients relapsed, and 10 patients received chemotherapy upon relapse. The median overall survival (OS) was 7.2 months and the one- and two-year OS rates were 32% and 12%, respectively. In a multivariate analysis, only the Karnofsky index was a prognostic factor. Hypofractionated radiotherapy and chemotherapy with temozolomide are feasible and acceptably tolerated in older patients. However, relevant prognostic factors are needed to optimize treatment proposals.http://www.mdpi.com/2072-6694/5/3/1177hypofractionated radiotherapychemotherapyelderly |
| spellingShingle | Georges Noël Pierre Kehrli Roland Schott Céline Vigneron Nicolas Bauer Jean-Baptiste Clavier Sokha Eav Hélène Nehme-Schuster Delphine Antoni Ludovic T. Nguyen Socheat Touch Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy Cancers hypofractionated radiotherapy chemotherapy elderly |
| title | Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy |
| title_full | Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy |
| title_fullStr | Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy |
| title_full_unstemmed | Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy |
| title_short | Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy |
| title_sort | outcomes in newly diagnosed elderly glioblastoma patients after concomitant temozolomide administration and hypofractionated radiotherapy |
| topic | hypofractionated radiotherapy chemotherapy elderly |
| url | http://www.mdpi.com/2072-6694/5/3/1177 |
| work_keys_str_mv | AT georgesnoel outcomesinnewlydiagnosedelderlyglioblastomapatientsafterconcomitanttemozolomideadministrationandhypofractionatedradiotherapy AT pierrekehrli outcomesinnewlydiagnosedelderlyglioblastomapatientsafterconcomitanttemozolomideadministrationandhypofractionatedradiotherapy AT rolandschott outcomesinnewlydiagnosedelderlyglioblastomapatientsafterconcomitanttemozolomideadministrationandhypofractionatedradiotherapy AT celinevigneron outcomesinnewlydiagnosedelderlyglioblastomapatientsafterconcomitanttemozolomideadministrationandhypofractionatedradiotherapy AT nicolasbauer outcomesinnewlydiagnosedelderlyglioblastomapatientsafterconcomitanttemozolomideadministrationandhypofractionatedradiotherapy AT jeanbaptisteclavier outcomesinnewlydiagnosedelderlyglioblastomapatientsafterconcomitanttemozolomideadministrationandhypofractionatedradiotherapy AT sokhaeav outcomesinnewlydiagnosedelderlyglioblastomapatientsafterconcomitanttemozolomideadministrationandhypofractionatedradiotherapy AT helenenehmeschuster outcomesinnewlydiagnosedelderlyglioblastomapatientsafterconcomitanttemozolomideadministrationandhypofractionatedradiotherapy AT delphineantoni outcomesinnewlydiagnosedelderlyglioblastomapatientsafterconcomitanttemozolomideadministrationandhypofractionatedradiotherapy AT ludovictnguyen outcomesinnewlydiagnosedelderlyglioblastomapatientsafterconcomitanttemozolomideadministrationandhypofractionatedradiotherapy AT socheattouch outcomesinnewlydiagnosedelderlyglioblastomapatientsafterconcomitanttemozolomideadministrationandhypofractionatedradiotherapy |